Subscribe To
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annual...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annual...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annual...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annual...
October 14, 2023, 8:30 pm
Black diamond therapeutics presents dose escalation data demonstrating durable responses in patients with nsclc from phase 1 trial of bdtx-1535
Initial results from BDTX-1535 dose escalation show durable activity in patients with NSCLC across heterogeneous EGFR mutation subtypes No new safety ...
October 14, 2023, 4:30 pm
Why enphase should likely be valued higher
Enphase Energy is a global leader in solar microinverter technology, offering best-in-class solar power...
October 14, 2023, 6:50 am
Gritstone bio: renewed excitement for its covid-19 vaccine
GRTS's COVID-19 vaccine may produce more durable immunity than current mRNA vaccines, according to data from p...
October 14, 2023, 2:21 am
Travere therapeutics to present abstracts at the american society of nephrology (asn) kidney week 2023
Two late-breaking high-impact oral presentations of the phase 3 PROTECT Study of FILSPARI® (sparsentan...
October 13, 2023, 8:30 pm
Relmada and rel-1017: intriguing underlying efficacy in mdd ahead of eventful 2024
phase 3 trial failures were due to abnormally high placebo responses driven by poor trial design, enrol...
October 13, 2023, 7:50 pm
Mind medicine: q4 of 2023 data for gad makes this worth a look
Results from the phase 2b study, using MM-120 for the treatment of patients with generalized anxiety di...
October 13, 2023, 6:37 pm
Alnylam pharmaceuticals: a good buy ahead of phase 3 data for vutrisiran
We rate Alnylam Pharmaceuticals, Inc.'s common stock a Buy on the dip after the complete response letter, CRL for Patisiran. The investment thesis is ...
October 13, 2023, 6:11 pm
Uaw strike against detroit automakers has entered 'new phase,' union boss says
The United Auto Workers strike against Ford, General Motors and Stellantis could be escalated at any time rather than on a weekly basis, the union's p...
October 13, 2023, 6:10 pm
Kronos bio presents positive preliminary data from phase 1 dose escalation portion of phase 1/2 kb-0742 study at aacr-nci-eortc
Demonstrated on-mechanism, single agent anti-tumor activity in heavily pre-treated patients with transcriptionally addicted solid tumors Showed manage...
October 13, 2023, 4:30 pm
Travere therapeutics to present abstracts at the american society of nephrology (asn) kidney week 2023
Two late-breaking high-impact oral presentations of the phase 3 PROTECT Study of FILSPARI ® (sparsenta...
October 13, 2023, 4:30 pm
Harmony stock tanks on study miss for narcolepsy drug: problems may be escalating
Harmony Biosciences' only product, WAKIX - pitolisant - has generated over $1 billion in net revenue since its launch. The company's Q2 2023 earnings ...
October 13, 2023, 4:01 pm
Syndax: biotech to watch with regulatory filings before end of 2023
Syndax Pharmaceuticals, Inc. reported positive results from its phase 1/2 trial using revumenib to trea...
October 13, 2023, 2:52 pm
Cidara therapeutics and mundipharma receive positive chmp opinion for rezafungin for the treatment of invasive candidiasis in adults(1)
The opinion was based on positive results from the pivotal ReSTORE phase III clinical trial and support...
October 13, 2023, 2:34 pm
Vera therapeutics to present three posters at the american society of nephrology kidney week 2023 annual meeting
Informational poster for ORIGIN 3 Pivotal phase 3 study evaluating atacicept in IgA Nephropathy (IgAN) ...
October 13, 2023, 2:22 pm
Annovis (anvs) ad study to continue as planned, shares rise
Annovis (ANVS) gains on the release of interim independent analysis, indicating that the ongoing phase ...
October 13, 2023, 2:16 pm
Gold seasonality trends: best months for investing
Like the blossom in spring and the harvest at the end of summer, gold shows recurring seasonal patterns or seasonality trends in its market performanc...
October 13, 2023, 1:26 pm